The Latest Breaking News on Pharma

US Drug Pricing Deal May Lead to Swiss Medicine Price Hikes

US drug price cuts may push up the cost of new medicines in Switzerland, Roche's CEO warns.

International Business Times · Dec 23, 2025

PPE company linked to ex-Tory peer Michelle Mone goes into liquidation

PPE Medpro owes government £148m for supplying unusable personal protective equipment during Covid-19 pandemic

The Guardian - UK · Dec 18, 2025

PPE Medpro wound up after being ordered to pay £148m to Government

The decision could mean that the Government is unlikely to see most of the £148 million owed to it by the company.

Evening Standard · Dec 18, 2025

Healthcare Relevancies Clashes With Premium Valuations For Direxion's LLY-Focused ELIL, ELIS ETFs

In terms of sheer relevance, it's difficult to think of a more relevant sector than healthcare — and within this vast ecosystem, only an elite few occupy the same neighborhood as pharmaceutical giant Eli Lilly and Company (NYSE:LLY). In November 2025, Eli Lilly became the first trillion-dollar pharmaceutical company, mostly…

Benzinga · Dec 8, 2025

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

International Business Times · Dec 8, 2025

Company linked to raid on illicit weight-loss drug facility still selling unlicensed drugs

Alluvi continues sales on Telegram after MHRA seized counterfeit, unlicensed retatrutide and tirzepatide pens

The Guardian - UK · Dec 7, 2025

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Praxis Precision Medicines Inc. (NASDAQ:PRAX) stock rose Friday after the company shared results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).

Benzinga · Dec 5, 2025

Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start

The U.S. Food and Drug Administration (FDA) placed a clinical hold on Denali Therapeutics Inc.’s (NASDAQ:DNLI) investigational new drug (IND) application for the Phase 1 study of DNL952 under development for Pompe disease.

Benzinga · Dec 5, 2025

FDA reaches "tipping point" after high-level departures

Biotech and pharmaceutical companies rely on the FDA for guidance as they spend huge sums developing treatments.

Axios · Dec 4, 2025

Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Shares of UiPath Inc. (NYSE:PATH) rose sharply in pre-market trading after the company reported upbeat third-quarter financial results and issued fourth-quarter sales guidance with its midpoint above estimates.

Benzinga · Dec 4, 2025